Financial Performance - Total revenue for 2025 was RMB 59,720.71 million, a decrease of 6.19% compared to the previous year[2] - Net profit attributable to shareholders was RMB 22,281.69 million, down 24.06% year-on-year[2] - Net profit excluding non-recurring gains and losses was RMB 19,141.86 million, a decline of 29.81% from the previous year[2] - Basic earnings per share decreased to RMB 2.77, down 23.90% compared to RMB 3.64 in the previous year[2] Assets and Equity - Total assets increased to RMB 267,401.41 million, reflecting a growth of 4.87% from the beginning of the period[2] - Shareholders' equity attributable to the parent company rose to RMB 251,585.13 million, an increase of 4.95%[2] Market Challenges and Strategies - The company faced challenges due to intensified competition in the minimally invasive endoscopic treatment sector and external factors like centralized procurement policies[7] - The company continued to invest in R&D and automation to enhance product competitiveness and maintain stable gross margins[7] - The company is focusing on global expansion, particularly in local operations in the Netherlands and the construction of a production base in Thailand[7] - High investments in R&D, production line updates, and market operations have impacted current profits but are expected to support future growth[7]

Core Viewpoint - The company reported a decline in revenue and net profit for the year 2025, attributed to industry factors such as domestic medical insurance centralized procurement and overseas tariff policies, as well as increased competition in the minimally invasive endoscopic treatment sector [1] Financial Performance - The company's total operating revenue for 2025 was 597.21 million yuan, a decrease of 6.19% compared to the same period last year [1] - The net profit attributable to the parent company's owners was 222.82 million yuan, down 24.06% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 191.42 million yuan, reflecting a decline of 29.81% compared to the previous year [1] Industry Context - The medical device industry faced challenges due to domestic medical insurance centralized procurement and overseas tariff policies, impacting the company's main business [1] - Increased competition in the minimally invasive endoscopic treatment field has contributed to the company's performance pressure in 2025 [1]

Group 1 - The core point of the article is that the company Anjisi has reported its shareholder count as of February 10, 2026, which stands at 6,341 households [2]

Core Insights - The company is focusing on new product launches, expansion into overseas markets, and obtaining medical device registrations for its subsidiaries [1] Product Development Progress - The second-generation bipolar product line is expected to receive regulatory approval by the end of 2025 and aims for full market promotion in 2026, which is anticipated to become a new growth driver [2] Business Progress - North American sales are expected to experience fluctuations due to tariff policies, but the company is advancing its shipping plans through its Thailand factory and plans to gradually expand to other overseas regions [3] Subsidiary Development - The company's controlling subsidiary received three Class II medical device registrations in December 2025, covering endoscopic equipment, with a validity period until December 2030, which will help enrich the product line, although the impact on future performance remains uncertain [4]

Group 1 - The core point of the article is that the company Anjisi has reported its shareholder count as of January 30, 2026, which stands at 6,314 households [1]

Group 1 - The first extraordinary general meeting of shareholders for 2026 was held on January 26, 2026, at the company's office in Hangzhou [2][3] - The total share capital as of the meeting's registration date was 81,122,079 shares, with 20,475 shares in the company's repurchase account not entitled to voting rights [2] - The meeting was convened by the board of directors and chaired by Chairman Zhang Cheng, utilizing a combination of on-site and online voting methods [3][4] Group 2 - Two ordinary resolutions were passed during the meeting: one regarding capital increase to a controlling subsidiary and another concerning providing guarantees for the controlling subsidiary [5][6] - The resolutions were approved by more than half of the voting rights held by shareholders present at the meeting, with separate counting for minority investors on the first resolution [6] - Related shareholders abstained from voting on the first resolution to avoid conflicts of interest [6] Group 3 - The meeting was witnessed by Beijing Deheng (Hangzhou) Law Firm, with lawyers Feng Lin and Yang Yang confirming that the meeting's procedures and resolutions complied with relevant laws and regulations [7]

证券代码：688581 证券简称：安杰思 公告编号：2026-005 杭州安杰思医学科技股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 1 月 26 日 本次股东会由公司董事会召集，董事长张承先生主持，会议采用现场投票和网络 投票相结合的表决方式。本次股东会的召集和召开程序、出席会议人员的资格和 召集人资格、会议的表决程序和表决结果均符合《中华人民共和国公司法》及《杭 州安杰思医学科技股份有限公司章程》的规定。 （五） 公司董事和董事会秘书的出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 70 | | --- | --- | | 普通股股东人数 | 70 | | 2、出席会议的股东所持有的表决权数量 | 54,747,120 | | 普通股股东所持有表决权数量 | 5 ...

北京德恒（杭州）律师事务所 关于杭州安杰思医学科技股份有限公司 2026 年第一次临时股东会的法律意见 北京德恒（杭州）律师事务所 关于杭州安杰思医学科技股份有限公司 2026年第一次临时股东会的 法律意见 德恒律师事务所 DeHeng Law Offices 电话:0571-86508080 传真:0571-87357755 邮编:310020 杭州市上城区新业路 200 号华峰国际商务大厦 10、11 楼 北京德恒（杭州）律师事务所 关于杭州安杰思医学科技股份有限公司 2026 年第一次临时股东会的法律意见 北京德恒（杭州）律师事务所 关于杭州安杰思医学科技股份有限公司 2026年第一次临时股东会的 法律意见 券法律业务执业规则（试行）》等规定及本法律意见出具日以前已经发生或者存 在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信用原则,进行了充分 的核查验证,保证本法律意见所认定的事实真实、准确、完整，所发表的结论性 意见合法、准确，不存在虚假记载、误导性陈述或者重大遗漏，并承担相应法律 责任。 本法律意见仅供公司本次股东会相关事项的合法性之目的使用，不得用作任 何其他目的。 本所律师根据法律的要求， ...

Group 1 - The core point of the article is that the company Anjisi has reported its shareholder count as of January 20, 2026, which stands at 6,458 households [1]

Core Viewpoint - The company emphasizes that Europe and EU member states are its primary markets, with a significant portion of its revenue generated from this region [1] Group 1: Revenue and Market Presence - By the third quarter of 2025, the company's revenue from the European market accounted for 23.66% of its total revenue [1] - The company's sales model in Europe primarily operates through the ODM model, exporting directly to European customers from domestic entities [1] Group 2: Operational Developments - The establishment of a subsidiary in the Netherlands has stabilized operations and enhanced the company's customer service capabilities and brand influence in the European market [1]